Women who develop hypoparathyroidism after surgery often have problems with bladder control, both on tests and in daily life, a small study found. The researchers recommended that checking urinary symptoms and bladder emptying be part of routine follow-up. The study, “Hypoparathyroidism is associated with bladder dysfunction, a preliminary…
Women, Hispanic patients, people who have other health problems, and those who have more lymph nodes removed are at higher risk of emergency visits for hypoparathyroidism after thyroid surgery, a study found. “Most risk factors identified are not modifiable, but they help identify high-risk patients who could benefit from…
Weekly treatment with MBX 2109, an experimental hormone replacement that MBX Biosciences is developing for chronic hypoparathyroidism, appears to be long-acting and to mimic natural parathyroid hormone (PTH) in healthy adults. Data come from a Phase 1 clinical trial (NCT05158335) where side effects reported with multiple doses…
Permanent hypoparathyroidism, which can occur when the parathyroid glands are accidentally removed along with the thyroid gland during a surgical procedure, increases the risk of kidney damage over time, according to a study by researchers in Hong Kong. “Careful patient selection and improvement in the identification and preservation of…
The U.S. Food and Drug Administration (FDA) has approved Ascendis Pharma’s Yorvipath (palopegteriparatide) as a parathyroid hormone replacement therapy for adults with hypoparathyroidism. The company expects to have the first supply ready in early 2025 after it completes manufacturing for the U.S. market. But if the FDA clears…
The U.S. Food and Drug Administration (FDA) is delaying by three months its decision to approve Ascendis Pharma’s TransCon PTH (palopegteriparatide) as a hormone replacement therapy for adults with hypoparathyroidism. The FDA decided not to approve the investigational therapy in April 2023 over concerns about its manufacturing…
TransCon PTH treatment continues to show benefits for up to a year in people with hypoparathyroidism, helping them achieve normal blood calcium levels and reducing the need for conventional therapy. That’s according to new data from PATHway (NCT04701203), a Phase 3 clinical trial wherein Ascendis Pharma…
About one in five people with Graves’ disease who undergo a thyroidectomy, which is the surgical removal of all or part of the thyroid gland, develop hypoparathyroidism, but most recover in less than six months. That’s according to a study looking back at the medical records of 216 people…
People who go on to develop hypoparathyroidism after surgery in the neck feel more tired and have less energy than control patients who do not develop the disease, a study from the U.K. has found. However, fatigue and low energy do not appear to reduce overall quality of life,…
People with hypoparathyroidism who are on replacement therapy with Natpara, a version of the parathyroid hormone (PTH), are about half as likely to develop chronic kidney disease than patients who don’t receive the therapy, a study found. The study, “The risk of chronic kidney disease development in…
Get regular updates to your inbox.
